Schweitzer Fachinformationen
Wenn es um professionelles Wissen geht, ist Schweitzer Fachinformationen wegweisend. Kunden aus Recht und Beratung sowie Unternehmen, öffentliche Verwaltungen und Bibliotheken erhalten komplette Lösungen zum Beschaffen, Verwalten und Nutzen von digitalen und gedruckten Medien.
Written by leading world experts, this third edition embraces the philosophy of international collaboration and disseminates the latest advances and transformative changes in the field of thyroid cancer.
The molecular landscape of thyroid cancers has a high frequency of oncogenic driver mutations and a high frequency of gene fusions treatable by new gene-specific systemic therapies. These include dual MAPK (Dabrafenib) / MEK (Trametinib) inhibition in BRAF V 600E mutated Anaplastic Thyroid Cancer, Larotrectinib, Entrectinib for NTRKgene fusion, Selpercartinib, Pralsetinib for RET fusion and mutations. These, newer and Master protocol trials, Tumour Agnostic drug development, Immune Checkpoint blockade and CAR-T therapy etc are discussed.
The latest NICE and African Guidelines for Management are included. This would be of interest to readers as well.
This book is aimed at thyroidologists of all disciplines, (in training or experts) students, non-specialist clinicians, nursing staff, all the disciplines involved in a multidisciplinary team such as surgeons - Head & Neck or Endocrine and General Surgeons, Oncologists, Endocrinologists, Nuclear Medicine Physicians, Nuclear Medicine Physicists, Radiologists, Pathologists, Specialist Nurses, Geneticists, Clinical Psychologists, Palliative Care Physicians and, in addition to AI in medicine, telemedicine experts, health policy makers, and scientists.
Dr Ujjal Mallick, MBBS MS FRCPE (Hon) FRCP (Hon) FRCR Consultant Clinical Oncologist Formerly Consultant Oncologist and past Chair, Multidisciplinary thyroid cancer team (MDT), Freeman Hospital, Newcastle upon Tyne, UK, a centre of excellence for thyroid cancer. Chief Investigator of the first UK National Thyroid Cancer Trial -Hilo-( NEJM 2012) which helped modify international guidelines and practice and of the on-going second UK trial-IoN. One of the lead authors of the first UK National guideline. The MDT obtained many prestigious national awards including-Best NHS "Hospital Doctor" Oncology Team of the Year" Award 2007, Best Thyroid cancer MDT in NHS Peer Review 2011, first prize in NHS innovations award 2007 and others. He initiated an acclaimed MD clinic involving an expert thyroid cancer patient. Current interests are trials, biomarkers and guideline implementation.
Dr Clive Harmer MB FRCR FRCP. Clinical Oncologist Consultant in Clinical Oncology at St. George's Healthcare NHS Trust and The Royal Marsden NHS Trust (where he was head of the Thyroid unit) until August 2005. Recognized teacher of the University of London and Honorary Senior Lecturer at the Institute of Cancer Research.
1. Pragmatism, Precision Oncology, International Partnership for Research and Quality-The New Paradigm for Thyroid Cancer.- Section I. Multidisciplinary Approach to Management of Thyroid Cancer.- 2. The UK Evidence-Based Guidelines for the Management of Thyroid Cancer: Key Recommendations.- 3. The 2015 American Thyroid Association Evidence-Based Guidelines for Management of Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Key Recommendations.- 4. Thyroid Cancer: One Doctor-Patient Partnership -The Newcastle Butterfly Model.- Section II. The Diagnosis of Thyroid Cancer.- 5. Molecular Diagnosis of Thyroid Nodules.- 6. Ultrasonography in Diagnosis and Management of Thyroid Cancer -Current International Recommendations .- Section III. Initial Thyroid Surgery.- 7. The 21st Century Endocrine Surgeon.- 8. Management of Cervical Lymph Nodes in Differentiated Thyroid Cancer.- 9. Advances in Thyroid Surgery.- Section IV. Non surgical Management ofDifferentiated Thyroid Cancer.- 10. Risk Stratification and Current Management of Low Risk Thyroid Cancer.- 11. Management of Low risk Papillary Thyroid Carcinomo and Papillary Cancer and Microcarcinoma-the Japanese experience.- 12. Radioiodine Ablation - Current Status.- 13. Dosimetric Approaches - Current Concepts.- 14. External Radiation in Differentiated Thyroid Cancer in the era of IMRT and modern radiation planning techniques.- Section V. Follow up and Longterm Management of Differentiated Thyroid Cancer.- 15. Thyroglobulin.- 16. Management of Post-Operative Hypocalcemia .- 17. Radioiodine Refractory Thyroid Cancer .- Section VI. Medullary Thyroid Carcinoma.- 18. Medullary Thyroid Cancer :Surgical Management.- 19. Medullary Thyroid Cancer: Diagnosis and Non Surgical Management.- 20. Familial Non-Medullary Thyroid Cancer.- Section VII. Thyroid Cancer in Children.- 21. Pediatric Differentiated Thyroid Carcinoma.- Section VIII. Aggressive ThyroidCancers.- 22. Anaplastic Thyroid Cancer.- 23. Palliative care.- Section IX. Future Developments and Directions for Research in Thyroid Cancer.- 24. Translational Research and Genomics Driven Trials in Thyroid Cancer.- 25. Thyroid Cancer Trials.- 26. The Barriers to Uniform Implementation of Clinical Practice Guidelines (CPG) for Thyroid Cancer.- 27. Survivorship: The Role of the Clinical Psychologist and the Clinical Nurse Specialist in Thyroid Cancer Care.
Dateiformat: PDFKopierschutz: Wasserzeichen-DRM (Digital Rights Management)
Systemvoraussetzungen:
Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Wasserzeichen-DRM wird hier ein „weicher” Kopierschutz verwendet. Daher ist technisch zwar alles möglich – sogar eine unzulässige Weitergabe. Aber an sichtbaren und unsichtbaren Stellen wird der Käufer des E-Books als Wasserzeichen hinterlegt, sodass im Falle eines Missbrauchs die Spur zurückverfolgt werden kann.
Weitere Informationen finden Sie in unserer E-Book Hilfe.
